AstraZeneca Vietnam has been honoured with the British Chamber of Commerce (BritCham)’s first-ever 50th Anniversary Recognition award. The award acknowledges the company’s unwavering commitment to innovation, sustainability, and its profound impact on Vietnam’s healthcare sector. This recognition comes as part Read More …
AstraZeneca Việt Nam vừa vinh dự nhận Giải thưởng 50th Anniversary Recognition lần đầu tiên được trao tặng bởi Hiệp hội Doanh nghiệp Anh Quốc tại Việt Nam (BritCham), nhân dịp kỷ niệm 50 năm thiết lập quan hệ ngoại Read More …
Chương trình AZ Forest hưởng ứng Đề án trồng một tỷ cây xanh giai đoạn 2021-2025 và Chiến lược quốc gia về biến đổi khí hậu giai đoạn đến năm 2050 của Chính Phủ Việt Nam Tập đoàn AstraZeneca vừa Read More …
AZ Forest programme to complement the Vietnamese Government’s plan to plant one billion trees by 2025 and National Strategy on Climate Change for 2050 AstraZeneca has announced a new investment of up to $50 million (1.2 trillion VND) into Vietnam, Read More …
Boosting with AstraZeneca’s vaccine and mRNA COVID-19 vaccines provide equally high protection against Omicron-related severe outcomes, including hospitalisation and death, even as new subvariants of the virus emerge, according to an expert review of more than 50 real-world studies. The Read More …
With more than 72 million doses delivered to Vietnam, AstraZeneca’s COVID-19 vaccine is one of the most used in the country and is estimated to have prevented 232,766 deaths locally, an independent assessment of vaccine effectiveness shows.1,2 AstraZeneca’s vaccine was Read More …
AstraZeneca Vietnam has recently been recognised with two awards from the British Chamber of Commerce (BritCham). These mark the latest acknowledgement of the company’s effort in almost three decades of contribution to sustainable healthcare development in Vietnam. While the company Read More …
Builds on initial US government agreement, now totalling 1.7 million doses Only antibody therapy authorized in the US for pre-exposure prophylaxis of COVID-19 in people who are immunocompromised AstraZeneca today announced the US Department of Health and Human Services has Read More …
University of Oxford study supports use of Vaxzevria as third dose booster against Omicron Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant AstraZeneca’s Read More …
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19 In this pre-clinical study, Evusheld’s Inhibitory Concentration 50 (IC50), a measure of neutralising potency of an antibody, was 171 ng/ml and 277 ng/ml in two confirmatory tests, which is within the Read More …
